Cargando…

MLL3 is a de novo cause of endocrine therapy resistance

BACKGROUND: Cancer resequencing studies have revealed epigenetic enzymes as common targets for recurrent mutations. The monomethyltransferase MLL3 is among the most recurrently mutated enzymes in ER+ breast cancer. The H3K4me1 marks created by MLL3 can define enhancers. In ER+ breast cancer, ERα gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Stauffer, Kimberly M., Elion, David L., Cook, Rebecca S., Stricker, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559462/
https://www.ncbi.nlm.nih.gov/pubmed/34581028
http://dx.doi.org/10.1002/cam4.4285